酶免疫组化和酶联免疫吸附试验在鼻咽癌普查中应用比较  

Comparison of IHCT and ELISA in the screening of nasopharyngeal carcinoma screening

作　　者：邓卓霞 翁敬锦[1] 麦稚平 王勇利[1] 黎炎成 覃扬达[1] 黄波[1] 兰桂萍[1] 司勇锋[1] DENG Zhuo-xia WENG Jing-jin MAI Zhi-ping WANG Yong-li LI Yan-cheng QIN Yang-da HUANG Bo LAN Gui-ping SI Yong-feng(Department of Otolaryngology Head and Neck Oncology, The People＇s Hospital of Guangxi Zhuang Autonomous Region, Nanning , Guangxi 530021, China)

机构地区：[1]广西壮族自治区人民医院耳鼻咽喉头颈肿瘤科鼻咽癌研究所,南宁530021 [2]广西梧州市苍梧县鼻咽癌防治所,广西梧州543100

出　　处：《中国病毒病杂志》2016年第2期125-129,共5页Chinese Journal of Viral Diseases

基　　金：广西科学研究与技术开发计划项目(桂科攻14124003-3;桂科攻14279008)

摘　　要：目的为探讨酶免疫组化法（enzyme immunohistochemistry technique,IHCT）和酶联免疫吸附试验（enzyme linked immunosorbent assay,ELISA）在鼻咽癌普查中的价值,并对两种检测方法的结果进行对比分析。方法 2013年8月分别应用酶免疫组化法和ELISA法同期检测3 843名健康人群的EB病毒抗原（酶免疫组化法）、EB病毒抗体（ELISA法：VCA-IgA和EBNA1-IgA）;根据EB病毒抗体水平对该人群分层评估：阳性组和阴性组（酶免疫组化法）;高危组、中危组和低危组（ELISA法）。结果酶免疫组化法阳性率为5.1%（196/3 843）,ELISA法阳性率为9.7%（374/3843）,两种方法均为阳性53例,阳性率差异有统计学意义（P〈0.01）。对酶免疫组化法阳性组和ELISA法高危组每6个月追踪随访至2015年7月31日,酶免疫组化法阳性组有7例确诊鼻咽癌,其中早期鼻咽癌（T1～2N0M0）6例,阴性组未确诊鼻咽癌;ELISA法高危组有1例确诊鼻咽癌,中危组（阳性组）299例患者有6例确诊鼻咽癌,低危组（阴性组）随访2年未发现鼻咽癌。结论 ELISA法联合酶免疫组化法有助于发现早期鼻咽癌,更适合鼻咽癌的普查。Objective To investigate the value of enzyme immunohistochemistry technique （IHCT） and Enzyme Linked Immunosorbent Assay （ELISA） at the nasopharyngeal carcinoma screening program. Methods Two serologic markers, VCA-IgA, Epstein-Barr virus nuclear antigen 1 （EBNAI-IgA）, were detected by ELISA and two traditional NPC screening serologic markers, VCA-IgA and EA-IgA, were detected by IHCT in serum samples from 3 843 healthy individuals in August 2013. The results were stratified according to the EB virus antibody levels., positive and negative groups （IHCT） ; high-risk, intermediate risk and low risk groups （ELISA）. Results EB virus antibody positive rate by IHCT and ELISA were 5.1% （196/3 843） and 9.7% （374/3 84.3）, respectively （P〈0.01）. The participants in EBV antibody-positive group （IHCT） and high-risk group （ELISA） were followed up every six months. Up to the July 31, 2015, seven patients were diagnosed with NPC in EBV antibody-positive group （IHCT）, among which 6 cases with early nasopharyngeal carcinoma （T1-2N0M0） . One patient was diagnosed with NPC in high-risk group, six NPC patients were confirmed in the moderate-risk group （positive group）. Conclusions ELISA combined IHCT method helps detect early nasopharyngeal carcinoma, and it is more suitable for NPC screening.

关 键 词：鼻咽癌 EB病毒抗体 酶免疫组化法 酶联免疫吸附试验 普查 

分 类 号：R739.63[医药卫生—肿瘤]